r SYRS Stock Quote - Syros Pharmaceuticals, Inc. Stock Price Today
TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds

Syros Pharmaceuticals, Inc.
(NASDAQ : SYRS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.14%78.631.2%$618.81m
AMGNAmgen Inc.
0.16%178.241.2%$557.24m
GILDGilead Sciences, Inc.
-0.22%67.380.9%$542.96m
BIIBBiogen Inc.
0.63%286.211.2%$478.24m
REGNRegeneron Pharmaceuticals, Inc.
-0.30%293.742.6%$304.78m
VRTXVertex Pharmaceuticals Incorporated
0.34%157.501.9%$219.69m
ALXNAlexion Pharmaceuticals, Inc.
0.51%117.742.0%$210.05m
ILMNIllumina, Inc.
-1.70%266.223.5%$198.41m
AAgilent Technologies, Inc.
-1.50%63.161.5%$196.40m
NKTRNektar Therapeutics
-0.77%79.966.0%$184.19m
INCYIncyte Corporation
2.64%68.432.5%$149.75m
BMRNBioMarin Pharmaceutical Inc.
4.77%92.494.4%$135.47m
SRPTSarepta Therapeutics, Inc.
1.85%91.6516.6%$126.22m
BLUEBluebird Bio, Inc.
0.62%188.1515.7%$98.65m
EXASExact Sciences Corporation
-1.95%51.8225.5%$98.64m

Company Profile

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The company focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. Syros Pharmaceuticals was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.